<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20080901001157N20</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-29</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>The effect of Artemisia herbal cream product on improving the symptoms of patients with psoriasis</public_title>
      <acronym></acronym>
      <scientific_title>Investigation of the safety and efficacy of Artemisia herbal cream product for the improvement and treatment of psoriasis skin patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-04-03</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69095</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random assignment to intervention and control groups. 
A random number table and block randomization method is used. In this method 60 eligible patients are assigned into 30 blocks of 2 patients. Then, each of the 2 patients in the block is randomly assigned to take herbal cream or standard cream, so that 30 patients assigned to each group, Blinding description: After making creams containing artemisia extract and creams containing Clobetasol (the main drug) and comparing the organoleptic characteristics of both types of creams, including color and smell, the creams were packed in a completely similar package and one person outside the study Creams containing artemisia extract or creams containing Clobetasol are assigned one of the two codes A or B so that the patients, the project managers, the specialist doctor and the person in charge of data analysis do not know about the content of creams A or B during the study. .</study_design>
      <phase>2</phase>
      <hc_freetext>Condition 1: Psoriasis. Condition 2: Other psoriasis. Condition 3: Moderate to severe psoriasis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: for 3 weeks, the patients of this group used a 60-gram tube of plant extract cream containing artemisia extract, wheat germ oil, jojoba oil, avocado oil, and pomegranate seed oil every night for 3 weeks. They use it locally on the lesions specified by the doctor. Intervention 2: Control group: The patients of this group use the cream containing Clobetasol topically on the lesions specified by the doctor, every night for 3 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Only the results are published in the form of articles.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nasrin Razavianzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University Blvd, Khatam al-Anbia hospital</address>
        <city>Shahrood</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3619943189</zip>
        <telephone>+98 23 3223 1442</telephone>
        <email>nasrinrazavianzadeh@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammadreza Gholibeikian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 26, Nader Alley, North Jamalzadeh St, Enghelab Square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1418635643</zip>
        <telephone>+98 21 6276 9000</telephone>
        <email>mgholibeikian@gmail.com</email>
        <affiliation>Homapharmed Company</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with psoriasis.
15 to 50 years old who are able to use the topical product.
Personal desire to participate in the project and the signing of a written consent.</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>People who are allergic to plant extracts and Artemisia annua plant extract.
pregnant women.
Lactating women.
Patients treated for systemic psoriasis 3 months before and during the study.
Patients who have a history of malignant disease, taking anti inflammatory and immunosuppressive drugs.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L40.0</hc_code>
      <hc_code>L40.8</hc_code>
      <hc_code>L40.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Psoriasis vulgaris</hc_keyword>
      <hc_keyword>Other psoriasis</hc_keyword>
      <hc_keyword>Generalized pustular psoriasis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: for 3 weeks, the patients of this group used a 60-gram tube of plant extract cream containing artemisia extract, wheat germ oil, jojoba oil, avocado oil, and pomegranate seed oil every night for 3 weeks. They use it locally on the lesions specified by the doctor.</i_keyword>
      <i_keyword>Control group: The patients of this group use the cream containing Clobetasol topically on the lesions specified by the doctor, every night for 3 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Erythema (redness) of Psoriasis rashes. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Observation.</prim_outcome>
      <prim_outcome>PASI number suitable for each patient (severity index of the psoriasis area). Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: The software for calculating the severity index of psoriasis area version 2.7.1.</prim_outcome>
      <prim_outcome>The thickness and prominence of psoriasis rashes. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Observation.</prim_outcome>
      <prim_outcome>Flaking. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Observation.</prim_outcome>
      <prim_outcome>Level of conflict. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Ruler (cm).</prim_outcome>
      <prim_outcome>Intensity of itching. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Using a visual scale with scoring by patients from 0 (no itching) to 10 (the most severe itching).</prim_outcome>
      <prim_outcome>Patient satisfaction. Timepoint: After completing the study. Method of measurement: VAS index (visual analog scale) which is a 10-point scale and shows the quality of the patient in the form of quantity with numbers.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Side effects of the drug. Timepoint: During the study. Method of measurement: Questionnaire and specialized visit by a dermatologist.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-02-15</approval_date>
        <contact_name>Research ethics Committees of Islamic Azad University, Shahrood Branch</contact_name>
        <contact_address>Islamic Azad University, Shahrood Branch Shahrood Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
